MX2022012917A - Composiciones anticonceptivas con efectos adversos reducidos. - Google Patents
Composiciones anticonceptivas con efectos adversos reducidos.Info
- Publication number
- MX2022012917A MX2022012917A MX2022012917A MX2022012917A MX2022012917A MX 2022012917 A MX2022012917 A MX 2022012917A MX 2022012917 A MX2022012917 A MX 2022012917A MX 2022012917 A MX2022012917 A MX 2022012917A MX 2022012917 A MX2022012917 A MX 2022012917A
- Authority
- MX
- Mexico
- Prior art keywords
- combined oral
- reduced risk
- adverse effects
- contraceptive
- reduced adverse
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002411 adverse Effects 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940127234 oral contraceptive Drugs 0.000 abstract 3
- 239000003539 oral contraceptive agent Substances 0.000 abstract 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000003217 oral combined contraceptive Substances 0.000 abstract 2
- 108010074051 C-Reactive Protein Proteins 0.000 abstract 1
- 102100032752 C-reactive protein Human genes 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 abstract 1
- 229950009589 estetrol Drugs 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000000757 progestagenic effect Effects 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un anticonceptivo oral combinado con un riesgo reducido de efectos secundarios, incluido un riesgo reducido de prolongación del intervalo QT, un riesgo reducido de disminución de testosterona y un riesgo reducido de niveles elevados de proteína C reactiva en comparación con otros anticonceptivos orales combinados. anticonceptivos El anticonceptivo oral combinado de estetrol/drospirenona descrito en el presente documento muestra una farmacocinética favorable para el componente progestágeno. El uso de un componente estrogénico específico en el anticonceptivo oral combinado conlleva múltiples beneficios sobre los anticonceptivos orales combinados actualmente disponibles.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169870 | 2020-04-16 | ||
| PCT/EP2021/059890 WO2021209591A1 (en) | 2020-04-16 | 2021-04-16 | Contraceptive compositions with reduced adverse effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012917A true MX2022012917A (es) | 2022-11-16 |
Family
ID=70292885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012917A MX2022012917A (es) | 2020-04-16 | 2021-04-16 | Composiciones anticonceptivas con efectos adversos reducidos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220211722A1 (es) |
| EP (1) | EP4135709A1 (es) |
| JP (1) | JP2023526580A (es) |
| KR (1) | KR20230004637A (es) |
| CN (1) | CN115666582A (es) |
| AR (1) | AR121864A1 (es) |
| AU (1) | AU2021255908A1 (es) |
| BR (1) | BR112022020710A2 (es) |
| CA (1) | CA3177556A1 (es) |
| IL (1) | IL297282A (es) |
| MX (1) | MX2022012917A (es) |
| TW (1) | TW202203935A (es) |
| UY (1) | UY39175A (es) |
| WO (1) | WO2021209591A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3106148T3 (es) | 2015-06-18 | 2018-08-11 | ||
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200046729A1 (en) * | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
| JOP20200169A1 (ar) * | 2018-02-07 | 2020-07-07 | Estetra Sprl | تركيبة لمنع الحمل بتأثيرات منخفضة على القلب والأوعية |
-
2021
- 2021-04-09 TW TW110112923A patent/TW202203935A/zh unknown
- 2021-04-16 UY UY0001039175A patent/UY39175A/es unknown
- 2021-04-16 KR KR1020227039906A patent/KR20230004637A/ko not_active Application Discontinuation
- 2021-04-16 MX MX2022012917A patent/MX2022012917A/es unknown
- 2021-04-16 CN CN202180038196.1A patent/CN115666582A/zh active Pending
- 2021-04-16 AU AU2021255908A patent/AU2021255908A1/en active Pending
- 2021-04-16 CA CA3177556A patent/CA3177556A1/en active Pending
- 2021-04-16 EP EP21716951.5A patent/EP4135709A1/en active Pending
- 2021-04-16 IL IL297282A patent/IL297282A/en unknown
- 2021-04-16 AR ARP210101014A patent/AR121864A1/es unknown
- 2021-04-16 BR BR112022020710A patent/BR112022020710A2/pt unknown
- 2021-04-16 JP JP2022562639A patent/JP2023526580A/ja active Pending
- 2021-04-16 WO PCT/EP2021/059890 patent/WO2021209591A1/en unknown
-
2022
- 2022-03-22 US US17/701,588 patent/US20220211722A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220211722A1 (en) | 2022-07-07 |
| WO2021209591A1 (en) | 2021-10-21 |
| KR20230004637A (ko) | 2023-01-06 |
| CA3177556A1 (en) | 2021-10-21 |
| EP4135709A1 (en) | 2023-02-22 |
| JP2023526580A (ja) | 2023-06-22 |
| TW202203935A (zh) | 2022-02-01 |
| AR121864A1 (es) | 2022-07-20 |
| AU2021255908A1 (en) | 2022-10-27 |
| CN115666582A (zh) | 2023-01-31 |
| BR112022020710A2 (pt) | 2022-12-20 |
| UY39175A (es) | 2022-04-29 |
| IL297282A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012917A (es) | Composiciones anticonceptivas con efectos adversos reducidos. | |
| Sitruk-Ware et al. | Contraception technology: past, present and future | |
| US6225298B1 (en) | Compositions and methods for contraception and for treatment of benign gynecological disorders | |
| GEP20227407B (en) | Contraceptive composition with reduced cardiovascular effects | |
| Sitruk-Ware et al. | Nestorone®: clinical applications for contraception and HRT | |
| JP2019163318A5 (es) | ||
| YU54602A (sh) | Drospirenon za terapiju zamene hormona | |
| EP2433951A3 (en) | A process for the preparation of drospirenone | |
| IL183645A0 (en) | Process for the preparation of drospirenone | |
| AR080861A1 (es) | Forma farmaceutica parenteral que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis | |
| JP2010508275A5 (es) | ||
| KR960704553A (ko) | 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen) | |
| CR10732A (es) | Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina | |
| RS20060348A (en) | Extended use combination comprising estrogens and progestins | |
| CO5580789A2 (es) | Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis | |
| US20010016578A1 (en) | Compositions and methods for contraception and for treatment of benign gynecological disorders | |
| Gemzell-Danielsson et al. | Mechanisms of action of mifepristone when used for emergency contraception | |
| Dhont et al. | Hormonal anticonception anno 2013: a clinician’s view | |
| SI1848406T1 (sl) | Trdna peroralna farmacevtska oblika za kontracepcijo, ki vsebuje dienogest in etinilestradiol | |
| EP1286666A2 (en) | Starter kit for low dose oral contraceptives | |
| SI1635843T1 (sl) | Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo | |
| JPH08510992A (ja) | 受精の阻止及び防止方法 | |
| Schindler | Non-contraceptive use of hormonal contraceptives | |
| WO2023152682A9 (en) | Contraceptive methods with scheduled bleeding effects | |
| Horne et al. | Medical therapies: progestins |